The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000330.4(RS1):c.175T>G (p.Cys59Gly)

CA412376057

2159556 (ClinVar)

Gene: RS1 (HGNC:6247)
Condition: X-linked retinoschisis (MONDO:0010725)
Inheritance Mode: X-linked inheritance (recessive (HP:0001419))
UUID: 40bed26c-a1bb-481d-a1b5-de875d47e07c
Approved on: 2025-10-03
Published on: 2025-10-03

HGVS expressions

NM_000330.4:c.175T>G
NM_000330.4(RS1):c.175T>G (p.Cys59Gly)
NC_000023.11:g.18656662A>C
CM000685.2:g.18656662A>C
NC_000023.10:g.18674782A>C
CM000685.1:g.18674782A>C
NC_000023.9:g.18584703A>C
NG_008659.3:g.25787T>G
ENST00000379984.4:c.175T>G
ENST00000379984.3:c.175T>G
NM_000330.3:c.175T>G
More

Pathogenic

Met criteria codes 6
PM5 PM1_Strong PP1_Strong PP4 PM2_Supporting PS4_Supporting
Not Met criteria codes 1
PP3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RS1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
X-linked Inherited Retinal Disease VCEP
NM_000330.4(RS1):c.175T>G (p.Cys59Gly) is a missense variant encoding the substitution of cysteine with glycine at amino acid 59, which is a critical amino acid residue involved in disulfide bridge formation as defined by the ClinGen X-linked IRD VCEP (PMID: 26812435, PM1_Strong). Another missense variant in the same codon, NM_000330.4(RS1):c.175T>A (p.Cys59Ser), (PMIDs: 31174210, 10450864, 17987333, 9618178) has been classified as pathogenic for X-linked retinoschisis by the ClinGen X-linked IRD VCEP, while no benign missense variants have been identified in this codon. The present variant has a higher Grantham’s distance (159) than the comparison variant (112), and SpliceAI has been used to confirm that neither variant has a predicted impact on RS1 splicing (PM5). This variant is absent from hemizygous individuals in gnomAD v4.1.0 (PM2_Supporting). At least one proband harboring this variant exhibits a phenotype including appearance of schisis and reduced visual acuity before age 13 years, which together are specific for X-linked retinoschisis (PMID: 34645606, PMID: 33460243, PP4). This variant has been reported in at least 1 other proband meeting the PS4 requirement of a male diagnosed with X-linked retinoschisis, in addition to the apparently unrelated proband previously used for the PP4 code (PMIDs: 30652005, PS4_Supporting). The variant has been reported to segregate with X-linked retinoschisis through at least 3 meioses in two families with multiple affected brothers (PP1_Strong; PMID: 30652005). The computational predictor REVEL gives a score of 0.868, which is within the linGen X-linked IRD VCEP range between 0.931 to 0.773 and predicts a damaging effect on RS1 function. PP3 is not met since this code is ineligible in combination with PM1_Strong. The computational splicing predictor SpliceAI gives a delta score of 0.00 for all predictive splice changes, which is below the ClinGen X-linked IRD VCEP threshold of >0.2 and does not predict that the variant disrupts RS1 splicing. In summary, this variant is classified as pathogenic for X-linked retinoschisis based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RS1 Version 1.0.0: PM2_Supporting, PM1_Strong, PP1_Strong, PP4, and PS4_Supporting.
Met criteria codes
PM5
Another missense variant in the same codon, NM_000330.4(RS1):c.175T>A (p.Cys59Ser), (PMIDs: 31174210, 10450864, 17987333, 9618178) has been classified as pathogenic for X-linked retinoschisis by the ClinGen X-linked IRD VCEP, while no benign missense variants have been identified in this codon. The present variant has a higher Grantham’s distance (159) than the comparison variant (112), and SpliceAI has been used to confirm that neither variant has a predicted impact on RS1 splicing (PM5).
PM1_Strong
This variant is a missense substitution affecting a critical amino acid residue involved in disulfide bridge formation as defined by the ClinGen X-linked IRD VCEP (PMID: 26812435, PM1_Strong).
PP1_Strong
The variant has been reported to segregate with X-linked retinoschisis through at least 3 meioses in two families with multiple affected brothers (PP1_Strong; PMID: 30652005).
PP4
At least one proband harboring this variant exhibits a phenotype including appearance of schisis and reduced visual acuity before age 13 years, which together are specific for X-linked retinoschisis (PMID: 34645606, PMID: 33460243, PP4).
PM2_Supporting
This variant is absent from hemizygous individuals in gnomAD v4.1.0 (PM2_Supporting).
PS4_Supporting
This variant has been reported in at least 1 proband meeting the PS4 requirement of a male diagnosed with X-linked retinoschisis, as well as a second apparently unrelated proband previously used for the PP4 code (PMIDs: 30652005, PS4_Supporting).
Not Met criteria codes
PP3
The computational predictor REVEL gives a score of 0.868, which is within the ClinGen X-linked IRD VCEP range between 0.931 to 0.773 and predicts a damaging effect on RS1 function. The computational splicing predictor SpliceAI gives a delta score of 0.00 for all predictive splice changes, which is below the ClinGen X-linked IRD VCEP threshold of >0.2 and does not predict that the variant disrupts RS1 splicing. The PM1_strong code is ineligible to be combined with PP3 at any strength, therefore, the PP3 code was not met.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.